# Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients

Source: https://onco.cc/trials/nct00168181/  
OnCo record `nct00168181` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pilocarpine in Head and neck squamous cell carcinoma, run by Alberta Health services, completed.

## Summary

Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients is a phase 3 interventional study registered as NCT00168181 by Alberta Health services, with 220 participants recorded, started 2002-04. Interventions recorded: Submandibular gland Transfer, Salagen. Conditions recorded: Cancer, Head and Neck Cancer.

Linked to the drug Pilocarpine because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00168181
- Phase: 3
- Setting: A Phase III Randomized Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients
- Sponsor: Alberta Health services
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT00168181: https://clinicaltrials.gov/study/NCT00168181

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Pilocarpine](https://onco.cc/drugs/pilocarpine/)

---
JSON: https://onco.cc/api/v1/entities/nct00168181.json